Mansour Alfayez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mansour Alfayez has a total of 181 co-authors. Here are the top co-authors by number of shared publications:
- Naval Daver
University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
31 shared publications - Bofei Wang
The University of Texas MD Anderson Cancer Center; Houston, United States
25 shared publications - Christopher Ly
Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030
25 shared publications - Fatima Zahra Jelloul
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
25 shared publications - Hussein A. Abbas
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
25 shared publications - Jairo Matthews
Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
25 shared publications
Latest Publications
- Open Access
- 6 March 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy
Exploratory analysis of CR and NR patients at baseline. CRs have significantly higher CD4 effector cytokine expression than NRs in the BM. No significant difference in functional group expression from CD8 cells in either PB and BM between CR and NR.
- 6 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy
Exploratory analysis of CR and NR patients at baseline. CRs have significantly higher CD4 effector cytokine expression than NRs in the BM. No significant difference in functional group expression from CD8 cells in either PB and BM between CR and NR.
- Open Access
- 6 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy
Baseline T cell individual cytokine activity in PB and BM.
- 6 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy
Baseline T cell individual cytokine activity in PB and BM.
- Open Access
- 6 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy
UMAP visualization depicting batch-corrected Seurat defined clusters.
- 6 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy
UMAP visualization depicting batch-corrected Seurat defined clusters.
- Open Access
- 6 March 2024
- Published by American Association for Cancer Research (AACR)
Data from Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy
Acute myeloid leukemia (AML) is a heterogeneous malignancy of the blood primarily treated with intensive chemotherapy. The allogeneic T-cell antileukemic activity via donor lymphocyte infusions and stem cell transplantation suggests a potential role for checkpoint blockade therapy in AML. While clinical trials employing these treatments have fallen short of expected results, a deeper exploration into the functional states of T cells in AML could bridge this knowledge gap. In this study, we analyzed the polyfunctional activity of T cells in a cohort of patients with relapsed/refractory (RelRef) AML treated on the clinical trial (ClinicalTrials.gov identifier: NCT02397720) of combination therapy using azacitidine and nivolumab (Aza/Nivo). We utilized the single-cell polyfunctional multiplexed immune assay IsoPlexis to evaluate the CD4 and CD8 T cells in peripheral blood and bone marrow samples collected before and after immunotherapy. This revealed at a pseudobulk level that the CD4 T cells exhibited higher functional activity post-immunotherapy (post-IO), suggesting that CD4-directed therapies may play a role in RelRef AML. Additional single-cell analysis revealed significant differences in baseline polyfunctionality in bone marrows of responders as compared with nonresponders for both CD4 and CD8 T cells. Overall, this study highlights the impact of polyfunctional assessment in understanding CD4 and CD8 dynamics in contexts of therapy in AML.Significance:We found T-cell polyfunctionality differs between local and systemic microenvironments. Enhanced variability in proteomic profiles of bone marrow CD4 T cells post-IO suggests their pivotal role in AML treatment response. Single-cell analysis identified novel CD4 and CD8 T-cell functional groups linked to immunotherapy response within the bone marrow.
- 6 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy
Acute myeloid leukemia (AML) is a heterogeneous malignancy of the blood primarily treated with intensive chemotherapy. The allogeneic T-cell antileukemic activity via donor lymphocyte infusions and stem cell transplantation suggests a potential role for checkpoint blockade therapy in AML. While clinical trials employing these treatments have fallen short of expected results, a deeper exploration into the functional states of T cells in AML could bridge this knowledge gap. In this study, we analyzed the polyfunctional activity of T cells in a cohort of patients with relapsed/refractory (RelRef) AML treated on the clinical trial (ClinicalTrials.gov identifier: NCT02397720) of combination therapy using azacitidine and nivolumab (Aza/Nivo). We utilized the single-cell polyfunctional multiplexed immune assay IsoPlexis to evaluate the CD4 and CD8 T cells in peripheral blood and bone marrow samples collected before and after immunotherapy. This revealed at a pseudobulk level that the CD4 T cells exhibited higher functional activity post-immunotherapy (post-IO), suggesting that CD4-directed therapies may play a role in RelRef AML. Additional single-cell analysis revealed significant differences in baseline polyfunctionality in bone marrows of responders as compared with nonresponders for both CD4 and CD8 T cells. Overall, this study highlights the impact of polyfunctional assessment in understanding CD4 and CD8 dynamics in contexts of therapy in AML.Significance:We found T-cell polyfunctionality differs between local and systemic microenvironments. Enhanced variability in proteomic profiles of bone marrow CD4 T cells post-IO suggests their pivotal role in AML treatment response. Single-cell analysis identified novel CD4 and CD8 T-cell functional groups linked to immunotherapy response within the bone marrow.
- Open Access
- 6 March 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy
Integrative analysis approach and clinical characteristic profile of patient cohort. A, Clinical characteristics of RelRef AML cohort for 21 patients involved in the phase II clinical trial. Among the 21 patients enrolled, 20 had baseline PB samples, 16 had baseline BM samples, 10 had posttreatment PB samples, and 6 had posttreatment BM samples. Four patients had prior allogeneic stem cell transplantation (all-SCT) therapy; 11 patients had prior HMA therapy; 11 patients had Secondary AML; 10 patients had CR to Aza/Nivo immunotherapy in the phase II clinical trial; Karyotype and molecular diagnostics at baseline for all 21 patients are included. B, Venn diagram visualizing the patient cohort.
- 6 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy
Integrative analysis approach and clinical characteristic profile of patient cohort. A, Clinical characteristics of RelRef AML cohort for 21 patients involved in the phase II clinical trial. Among the 21 patients enrolled, 20 had baseline PB samples, 16 had baseline BM samples, 10 had posttreatment PB samples, and 6 had posttreatment BM samples. Four patients had prior allogeneic stem cell transplantation (all-SCT) therapy; 11 patients had prior HMA therapy; 11 patients had Secondary AML; 10 patients had CR to Aza/Nivo immunotherapy in the phase II clinical trial; Karyotype and molecular diagnostics at baseline for all 21 patients are included. B, Venn diagram visualizing the patient cohort.
- Open Access
- 6 March 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 4 from Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy
Single-cell analysis of IsoPlexis data for CD4 cells (left) and CD8 cells (right). A, UMAP visualization colored by sample location (orange for PB, purple for BM). B, UMAP colored by time point (green for baseline, pink for post-therapy). C, Neighborhood graph depicting differential abundance testing results obtained from miloR. Colors represent the log fold-change between baseline (red) and post-IO (blue) cells. White neighborhoods are nondifferential (FDR 10%). The edges depict links between cells shared by neighborhoods. D, Beeswarm plot of the distribution of neighborhoods by timepoint. E, Beeswarm plot of the distribution of neighborhoods by UMAP-based cluster.
- 6 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 4 from Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy
Single-cell analysis of IsoPlexis data for CD4 cells (left) and CD8 cells (right). A, UMAP visualization colored by sample location (orange for PB, purple for BM). B, UMAP colored by time point (green for baseline, pink for post-therapy). C, Neighborhood graph depicting differential abundance testing results obtained from miloR. Colors represent the log fold-change between baseline (red) and post-IO (blue) cells. White neighborhoods are nondifferential (FDR 10%). The edges depict links between cells shared by neighborhoods. D, Beeswarm plot of the distribution of neighborhoods by timepoint. E, Beeswarm plot of the distribution of neighborhoods by UMAP-based cluster.
- Open Access
- 6 March 2024
- Published by American Association for Cancer Research (AACR)
Data from Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy
Acute myeloid leukemia (AML) is a heterogeneous malignancy of the blood primarily treated with intensive chemotherapy. The allogeneic T-cell antileukemic activity via donor lymphocyte infusions and stem cell transplantation suggests a potential role for checkpoint blockade therapy in AML. While clinical trials employing these treatments have fallen short of expected results, a deeper exploration into the functional states of T cells in AML could bridge this knowledge gap. In this study, we analyzed the polyfunctional activity of T cells in a cohort of patients with relapsed/refractory (RelRef) AML treated on the clinical trial (ClinicalTrials.gov identifier: NCT02397720) of combination therapy using azacitidine and nivolumab (Aza/Nivo). We utilized the single-cell polyfunctional multiplexed immune assay IsoPlexis to evaluate the CD4 and CD8 T cells in peripheral blood and bone marrow samples collected before and after immunotherapy. This revealed at a pseudobulk level that the CD4 T cells exhibited higher functional activity post-immunotherapy (post-IO), suggesting that CD4-directed therapies may play a role in RelRef AML. Additional single-cell analysis revealed significant differences in baseline polyfunctionality in bone marrows of responders as compared with nonresponders for both CD4 and CD8 T cells. Overall, this study highlights the impact of polyfunctional assessment in understanding CD4 and CD8 dynamics in contexts of therapy in AML.Significance:We found T-cell polyfunctionality differs between local and systemic microenvironments. Enhanced variability in proteomic profiles of bone marrow CD4 T cells post-IO suggests their pivotal role in AML treatment response. Single-cell analysis identified novel CD4 and CD8 T-cell functional groups linked to immunotherapy response within the bone marrow.
- 6 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy
Acute myeloid leukemia (AML) is a heterogeneous malignancy of the blood primarily treated with intensive chemotherapy. The allogeneic T-cell antileukemic activity via donor lymphocyte infusions and stem cell transplantation suggests a potential role for checkpoint blockade therapy in AML. While clinical trials employing these treatments have fallen short of expected results, a deeper exploration into the functional states of T cells in AML could bridge this knowledge gap. In this study, we analyzed the polyfunctional activity of T cells in a cohort of patients with relapsed/refractory (RelRef) AML treated on the clinical trial (ClinicalTrials.gov identifier: NCT02397720) of combination therapy using azacitidine and nivolumab (Aza/Nivo). We utilized the single-cell polyfunctional multiplexed immune assay IsoPlexis to evaluate the CD4 and CD8 T cells in peripheral blood and bone marrow samples collected before and after immunotherapy. This revealed at a pseudobulk level that the CD4 T cells exhibited higher functional activity post-immunotherapy (post-IO), suggesting that CD4-directed therapies may play a role in RelRef AML. Additional single-cell analysis revealed significant differences in baseline polyfunctionality in bone marrows of responders as compared with nonresponders for both CD4 and CD8 T cells. Overall, this study highlights the impact of polyfunctional assessment in understanding CD4 and CD8 dynamics in contexts of therapy in AML.Significance:We found T-cell polyfunctionality differs between local and systemic microenvironments. Enhanced variability in proteomic profiles of bone marrow CD4 T cells post-IO suggests their pivotal role in AML treatment response. Single-cell analysis identified novel CD4 and CD8 T-cell functional groups linked to immunotherapy response within the bone marrow.
- Open Access
- 6 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy
Supplementary Table 1. Clinical Characteristics.
- 6 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy
Supplementary Table 1. Clinical Characteristics.
- Open Access
- 6 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy
Baseline and post-therapy T cell functional activity within PB and BM.
- 6 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy
Baseline and post-therapy T cell functional activity within PB and BM.
- Open Access
- 6 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy
Baseline correlation analysis of age with individual cytokines and functional groups.
- 6 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy
Baseline correlation analysis of age with individual cytokines and functional groups.